WSGR logoWSGR logo
Payal Vyas
Patent Agent
Patents and Innovations
Boston

D617-598-7842

Download vCard
Open PDF

Dr. Payal Vyas is a patent agent in the Boston office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. Payal has diverse scientific expertise in a variety of fields and emerging technologies including molecular and cell biology, gene editing and therapy, biochemistry, biophysics, microbiology, microscopy, cancer biology, and cardiovascular sciences.

Payal completed her postdoctoral training at The Center for Interdisciplinary Cardiovascular Sciences (CICS) at Harvard Medical School and the Brigham and Women's Hospital, where she led research projects focused on discovery of therapeutic targets and drug development for cardiac calcification using high throughput proteomic and transcriptomic approaches.

Before joining CICS, Payal was a research fellow at Massachusetts General Hospital, Broad institute, and Harvard Medical School. In this role, she studied drug resistance and dormancy in solid tumors. Payal was part of the patent law and technology commercialization internship program at Partners HealthCare Innovation, where she assessed patentability and commercialization potential of technologies developed at Harvard Medical School and affiliated hospitals.

Prior to joining the firm, Payal was a patent specialist in the Boston office of Nixon Peabody LLP. In this role, she gained experience in drafting and prosecution of patent applications related to CRISPR-Cas9, RNA interference, cancer biology, stem cells, immunotherapy, tissue regeneration, and the discovery of diagnostics and therapeutics using machine learning. During her doctoral studies, she studied chromatin structure and function and developed live-cell imaging approaches to visualize and measure histone dynamics.

Experience

Dr. Payal Vyas is a patent agent in the Boston office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. Payal has diverse scientific expertise in a variety of fields and emerging technologies including molecular and cell biology, gene editing and therapy, biochemistry, biophysics, microbiology, microscopy, cancer biology, and cardiovascular sciences.

Payal completed her postdoctoral training at The Center for Interdisciplinary Cardiovascular Sciences (CICS) at Harvard Medical School and the Brigham and Women's Hospital, where she led research projects focused on discovery of therapeutic targets and drug development for cardiac calcification using high throughput proteomic and transcriptomic approaches.

Before joining CICS, Payal was a research fellow at Massachusetts General Hospital, Broad institute, and Harvard Medical School. In this role, she studied drug resistance and dormancy in solid tumors. Payal was part of the patent law and technology commercialization internship program at Partners HealthCare Innovation, where she assessed patentability and commercialization potential of technologies developed at Harvard Medical School and affiliated hospitals.

Prior to joining the firm, Payal was a patent specialist in the Boston office of Nixon Peabody LLP. In this role, she gained experience in drafting and prosecution of patent applications related to CRISPR-Cas9, RNA interference, cancer biology, stem cells, immunotherapy, tissue regeneration, and the discovery of diagnostics and therapeutics using machine learning. During her doctoral studies, she studied chromatin structure and function and developed live-cell imaging approaches to visualize and measure histone dynamics.

Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises Vida Ventures on IP Matters Related to Third Arc Bio's $165 Million Series A Round
On July 23, 2024, Third Arc Bio Inc., a biotech company developing multifunctional antibodies optimized for T cell engagement across solid tumors and inflammatory & immunology (I&I) disease, announced a $165 million oversubscribed Series A financing that will advance the company through clinical studies to address significant unmet needs in oncology and autoimmunity. The company was launched in 2022 with seed financing from Omega Funds and has since advanced multiple programs that will enter the clinic starting in early 2025. The Series A investor syndicate was led by Vida Ventures and co-led by Cormorant Asset Management and Hillhouse Investment. Omega Funds continued their strong support of the company in the Series A and additional investors include Goldman Sachs Alternatives, BVF Partners LP, funds and accounts advised by T. Rowe Price Associates, Inc., Janus Henderson Investors, funds managed by abrdn Inc., Marshall Wace, Foresite Capital, Logos Capital, Freepoint Capital Group, and AbbVie Ventures.
Learn More
Client Highlights
Wilson Sonsini Advises Chroma Medicine on $135 Million Series B Financing
On March 1, 2023, genomic medicine company Chroma Medicine announced that it had completed a $135 million Series B financing, which was led by GV (Google Ventures). The financing included additional participation from new investors ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, and all of its existing investors, including Alexandria Venture Investments, Atlas Venture, Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, and Wellington Management. Wilson Sonsini Goodrich & Rosati represented Chroma Medicine on the transaction.
Learn More
View All
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.